An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer

NCT06560112 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Ovarian Cancer

Interventions

DRUG: AK104
DRUG: AK112
DRUG: Chemotherapy

Sponsor

Akeso